Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 20/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940427 | 0.87 | MKNK1 (0.60) | MKNK1FYNMKNK2 | |
| SCHEMBL2945059 | 0.79 | FYN (0.45) | MKNK1FYNMKNK2 | |
| SCHEMBL14771339 | 0.79 | MKNK1 (0.74) | MKNK1FYNMKNK2 | |
| SCHEMBL15921290 | 0.78 | MKNK1 (0.73) | MKNK1FYNMKNK2 | |
| SCHEMBL2949526 | 0.77 | PIK3CD (0.52) | MKNK1FYNMKNK2 | |
| SCHEMBL13859054 | 0.76 | MKNK1 (1.00) | MKNK1FYNMKNK2 | |
| SCHEMBL19336870 | 0.76 | MKNK1 (0.73) | MKNK1MKNK2 | |
| SCHEMBL30521685 | 0.75 | MKNK1 (1.00) | MKNK1FYN | |
| SCHEMBL2950870 | 0.75 | MKNK1 (1.00) | MKNK1FYN | |
| SCHEMBL14764375 | 0.75 | MKNK1 (0.64) | MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | MKNK1 144/4885FYN 421/4885MKNK2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.